Gerresheimer AG (GXI) Fair Value & Analysis
Healthcare · DE · Market cap €939M
Fair value as of: Jun 24, 2026
From 15 valuation models · updated 6 days ago
Fair value updated Jun 24, 2026 — revised from €36.92 to €57.32 (+55.3%) since Jun 23, 2026. Share price +2.3% over the past month.
Price vs Fair Value (12 months)
12‑month range €15.46 – €49.84 · fair‑value band €40.12 – €74.52 · the €27.40 price screens below the €57.32 fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Gerresheimer AG (GXI) currently trades at €27.40, while our model-based Fair Value estimate is €57.32 — implying the stock looks roughly 109.2% undervalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Gerresheimer AG generated revenue of €2.3B at a net margin of 1.0%. Revenue grew 12.5% year over year. It earns a return on equity of 1.8%. Net debt stands at €1.1B. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Gerresheimer AG, together with its subsidiaries, provides medicine packaging, drug delivery devices, and solutions in Germany and internationally. The company operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. It offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and containers, bottles, caps, closures, applicators, and accessories; development, industrialization and contract manufacturing of drug delivery programs; project and quality management; and drug delivery devices, including inhalers, injection/auto injectors, and pen injectors. The company also provides diagnostic and medical devices comprising point-of-care tests, laboratory disposables, chemical and technical bottles, diagnostic and polymer vials, dropper bottles, PET bottles, and medical products comprising lancing devices, infusion sets, and disposable systems. In addition, it offers cos…
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Gerresheimer AG reported revenue of €2.0B in FY2024 versus €1.4B in FY2020, a compound +9.4%/yr. Reported net income was €110M in FY2024, compounding +5.5%/yr from FY2020.
Open the full interactive analysis →
Similar stocks
6 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $412.02 | $165.35 | -60% |
| EssilorLuxottica Société anonyme ESLOF | $192.00 | $126.51 | -34% |
| HOYA Corporation HOCPY | $168.16 | $96.16 | -43% |
| Medline Inc MDLN | $34.71 | $30.15 | -13% |
| Becton, Dickinson and Company BDX | $140.71 | $104.17 | -26% |
| Alcon Inc ALC | $66.58 | $36.99 | -44% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Gerresheimer AG (GXI) undervalued?
What is the fair value of GXI?
What is the quality score of GXI?
What is the revenue of Gerresheimer AG (GXI)?
What is the net profit margin of GXI?
Does Gerresheimer AG pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.